Psilocybin, a natural psychoactive compound currently being considered for the treatment of depression, alters people's emotional states while listening to music. While listening to music, those who used psilocybin reported enhanced emotional processing. Researchers say combining music with psychedelic therapy may have positive benefits for those suffering from depression.
In the absence of neural activity, BDNF expression can still be activated. The findings shed light on how therapeutic ketamine used has an antidepressant effect and how it works in both the long and short term.
Allopregnanolone, a neuroactive steroid used in the treatment of postpartum depression, alters neural communication in the basolateral amygdala, an area of the brain associated with emotion and mood regulation. The drug may alter the network associated with chronic stress, which may explain its persistent antidepressant effect.
A new study adds to the growing body of research linking inflammation to depression. Researchers found the molecule histamine directly inhibits the release of serotonin in the brain by attaching to inhibitory receptors on serotonin neurons in mice.
Taking SSRI antidepressants does not increase the risk of developmental delays or autism in children, a new study reports. However, there is an increased risk for ASD and developmental delays in children whose mothers suffer from maternal psychiatric disorders.
Prescribing SSRIs during late childhood to those with genetic risk factors for psychosis can reduce the deterioration of intellectual abilities, a new study reveals. SSRIs appear to have a neuroprotective effect for certain brain areas associated with the onset of psychosis if provided early.
A new study reveals the molecular and cellular mechanisms behind why some people find it harder to stop using antidepressants than others with depression.
Psilocybin, the psychoactive compound found in magic mushrooms, is as effective at treating depression as conventional SSRI antidepressants. Researchers report, that although not significantly significant, early findings reveal those treated with psilocybin experienced more rapid and greater reductions in depression symptoms than those treated with SSRIs.
A mouse study refutes the common belief that psilocybin's ability to produce an anti-depressant effect is attributed to the psychedelic experience it creates. Blocking the psychedelic effect did not affect psilocybin's anti-depressant effects.